LIQUID PREPARATION OF PHYSIOLOGICALLY ACTIVE PEPTIDE
    41.
    发明申请
    LIQUID PREPARATION OF PHYSIOLOGICALLY ACTIVE PEPTIDE 有权
    液体制备生理活性肽

    公开(公告)号:US20110077195A1

    公开(公告)日:2011-03-31

    申请号:US12848638

    申请日:2010-08-02

    摘要: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.

    摘要翻译: 有效的液体制剂实现了作为药物施用的生理活性肽或蛋白质(包括生长素释放肽)的高生物利用度(BA)。 还提供了一种用于改善皮下注射在水溶液中的生理活性肽或蛋白质(包括生长素释放肽)的BA的方法。 液体制剂含有:生理活性肽或蛋白质,如生长素释放肽,作为活性成分; 包括选自乙酸,乳酸,磷酸,甘氨酸,柠檬酸,盐酸,丙酸,丁酸,苯甲酸及其盐中的一种或两种以上组合的酸溶液; 酒精; 以及包含选自N-甲基-2-吡咯烷酮,二甲基甲酰胺,二甲基亚砜和对羟基苯甲酸甲酯中的一种或两种以上的组合的极性有机液体。

    PORTABLE TERMINAL
    42.
    发明申请
    PORTABLE TERMINAL 失效
    便携式终端

    公开(公告)号:US20100044203A1

    公开(公告)日:2010-02-25

    申请号:US12594129

    申请日:2008-06-25

    IPC分类号: H01H13/76

    摘要: In a portable terminal, a plurality of operation keys 7 are formed in a key through hole, which is formed in a housing main body that covers a printed board 15, by partitioning a stainless steel sheet 26 (a key sheet) by slits 26a. A urethane sheet 28 is attached to the rear side of the stainless steel sheet 26, where the urethane sheet 28 has ridge portions 28a that bulge out through the slits 26a to the front side of the stainless steel sheet 26, and the rear sides of the ridge portions 28a have groove-like openings. A rubber layer 29 is attached to the rear side of the urethane sheet 28, where the rubber layer 29 has a plurality of protruding portions 23 that protrudes toward a substrate 25 at positions corresponding to a plurality of fixed contacts 16 over the substrate 25. LEDs (light emitting means) and a light guide sheet 21 are disposed closer to the substrate than the rubber layer 29 is. Recess grooves 29a (wrong operation preventing means), for preventing the operation keys 7 located adjacent to each ridge portion 28a from being depressed at the same time, are formed in the rubber layer 29 at locations corresponding to the rear sides of the ridge portions 28a. This implements the operation keys 7 that have a nice feel and are less likely to cause wrong operation, while uniformly guiding light from the LEDs to the operation keys 7.

    摘要翻译: 在便携式终端中,通过利用狭缝26a分隔不锈钢板26(钥匙片),形成在形成在覆盖印刷电路板15的壳体主体内的钥匙通孔中的多个操作键7。 聚氨酯片28安装在不锈钢片26的后侧,其中聚氨酯片28具有通过狭缝26a向不锈钢片26的前侧凸出的脊部28a, 脊部28a具有槽状开口。 橡胶层29附着在聚氨酯片28的后侧,橡胶层29具有多个突出部23,该突出部23在与衬底25上的多个固定触点16相对应的位置处朝向衬底25突出。LED (发光装置)和导光片21比橡胶层29更靠近基板设置。 在对应于脊部28a的后侧的位置处,在橡胶层29中形成有用于防止位于与每个脊部28a相邻的操作键7同时被压下的凹槽29a(错误操作防止装置) 。 这实现了具有良好感觉的操作键7,并且不太可能导致错误的操作,同时将来自LED的光均匀地引导到操作键7。

    Liquid Preparation of Physiologically Active Peptide
    43.
    发明申请
    Liquid Preparation of Physiologically Active Peptide 审中-公开
    液体制备生理活性肽

    公开(公告)号:US20080193997A1

    公开(公告)日:2008-08-14

    申请号:US11660406

    申请日:2005-08-24

    IPC分类号: C12N9/94

    摘要: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.

    摘要翻译: 有效的液体制剂实现了作为药物施用的生理活性肽或蛋白质(包括生长素释放肽)的高生物利用度(BA)。 还提供了一种用于改善皮下注射在水溶液中的生理活性肽或蛋白质(包括生长素释放肽)的BA的方法。 液体制剂含有:生理活性肽或蛋白质,如生长素释放肽,作为活性成分; 包括选自乙酸,乳酸,磷酸,甘氨酸,柠檬酸,盐酸,丙酸,丁酸,苯甲酸及其盐中的一种或两种以上组合的酸溶液; 酒精; 以及包含选自N-甲基-2-吡咯烷酮,二甲基甲酰胺,二甲基亚砜和对羟基苯甲酸甲酯中的一种或两种以上的组合的极性有机液体。

    Medical compositions containing ghrelin
    44.
    发明申请
    Medical compositions containing ghrelin 有权
    含有生长素释放肽的医药组合物

    公开(公告)号:US20080081787A1

    公开(公告)日:2008-04-03

    申请号:US11878532

    申请日:2007-07-25

    IPC分类号: A61K38/17 C07K14/575

    摘要: It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to 7 is a buffer solution, especially, glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer, and the concentration of the ghrelins in the solution is from 0.03 nmol/mL to 6 μmol/mL.

    摘要翻译: 提供了稳定地含有生长激素促分泌素受体(GHS-R)的生长激素促分泌素(GHS)的生长素释放肽或其衍生物的药物组合物,其包含含有pH范围为2至7的生长素释放肽的水溶液 其中pH范围为2-7的水溶液是缓冲溶液,特别是甘氨酸盐酸缓冲液,乙酸盐缓冲液,柠檬酸盐缓冲液,乳酸盐缓冲液,磷酸盐缓冲液,柠檬酸 - 磷酸盐缓冲液,磷酸盐 - 乙酸盐 - 硼酸盐缓冲液或邻苯二甲酸盐缓冲液 ,并且溶液中生长素释放肽的浓度为0.03nmol / mL至6mumol / mL。

    Continuous riveting machine for fastening blind rivets
    49.
    发明授权
    Continuous riveting machine for fastening blind rivets 失效
    用于紧固盲铆钉的连续铆接机

    公开(公告)号:US5651169A

    公开(公告)日:1997-07-29

    申请号:US692727

    申请日:1996-08-06

    摘要: Although the conventional continuous riveting machine was able to use exclusively a special blind rivet having a longer core-stem than that of the standard type, the continuous riveting machine according to the present invention is able to use the standard blind rivet and also able to recover separately torn core rivet stems and a blind rivet-holding belt made of plastic material enabling the supply of blind rivets in series. When a lower piston 600 descends in a jaw cylinder 400, a nose piece 620 integrated in one piece with the lower piston 600 also descends while bending downwardly plastic upper and lower tabs of the blind rivet-holding belt, and holding the blind rivet. Torn-core-stems are absorbed and stored in a torn core rivet stems storing case installed on the upper portion of the jaw cylinder by applying vacuum air absorbing force generated in a vacuum ejector.

    摘要翻译: 虽然传统的连续铆接机只能使用具有比标准型更长的芯杆的特殊的盲铆钉,但根据本发明的连续铆接机能够使用标准的盲铆钉并且还能够恢复 单独撕裂的芯铆钉杆和由塑料材料制成的盲铆钉保持带,能够串联供应盲铆钉。 当下活塞600在颚缸400中下降时,与下活塞600集成成一体的鼻片620也向下弯曲,同时向下弯曲盲铆钉保持带的塑料上下片,并保持盲铆钉。 撕心芯通过在真空喷射器中产生的真空空气吸收力被吸收并储存在安装在颚缸上部的撕裂芯铆钉杆的储存箱中。

    Method for the measurement of serum bile acids by elisa and method for
the diagnosis of liver disease
    50.
    发明授权
    Method for the measurement of serum bile acids by elisa and method for the diagnosis of liver disease 失效
    elisa血清胆汁酸测定方法及肝脏疾病诊断方法

    公开(公告)号:US5631138A

    公开(公告)日:1997-05-20

    申请号:US381497

    申请日:1995-01-31

    摘要: A method for the measurement of serum bile acids by ELISA comprising: preparing a bile acid active ester, reacting the ester with a bovine serum albumin solution, dialyzing, and immunizing a mammal other than human being with the dialyzate thus obtained as an antigen to thereby give an anti-bile acid antibody; reacting said active ester with an enzyme to thereby prepare an enzyme-labeled bile acid as an enzyme-labeled antigen; to a secondary antibody-coated plate, adding a dilution of the serum to be assayed, an anti-bile acid antibody solution and an enzyme-labeled antigen solution and reacting these substances followed by the addition of a substrate and the reaction therewith; measuring the absorbance of the reaction mixture and determining the concentration of each bile acid on the basis of the standard curve measured simultaneously; and referring the sum of the concentrations of these bile acids to the total bile acid concentration; and a method for the diagnosis of a liver disease comprising: calculating the concentration ratio of each bile acid from the values measured by the former method; and comparing the concentration ratio thus obtained with the standard level scope of said concentration ratio obtained from healthy subjects are provided.

    摘要翻译: 一种用于通过ELISA测量血清胆汁酸的方法,其包括:制备胆汁酸活性酯,使所述酯与牛血清白蛋白溶液反应,透析并用由此获得的透析液作为抗原免疫除人之外的哺乳动物,由此 给予抗胆汁酸抗体; 使所述活性酯与酶反应,从而制备酶标记的胆汁酸作为酶标记的抗原; 添加到待测细胞的稀释液,抗胆汁酸抗体溶液和酶标记的抗原溶液中,然后使这些物质反应,然后加入底物和与其反应; 测量反应混合物的吸光度,并根据同时测量的标准曲线测定每种胆汁酸的浓度; 并将这些胆汁酸的浓度之和表示为总胆汁酸浓度; 以及用于诊断肝脏疾病的方法,包括:从通过前一种方法测量的值计算每种胆汁酸的浓度比; 并比较由此获得的浓度比与从健康受试者获得的所述浓度比的标准水平范围。